Updates for March 27 – April 2, 2018 – China steps up control over technology exports

China steps up scrutiny of IP transfers to foreign firms on national security grounds Under new regulations issued by the State Council on Thursday, technology transfers include IP transfers that are part of acquisitions made by foreign firms involving patents, integrated circuit layout design, computer software copyright and plant varieties. Such transfers will be assessed in terms of their impact on national security and the country’s “key technology innovation capability in key areas,” said the document.

This move is not intended to “upset foreign investors” but rather to formulate “concrete measures to secure a better business environment,” said Zhang Zhicheng, director of the Protection and Coordination Department at SIPO. Zhang also noted the importance for China to strictly review core IP transfers.
Our preliminary observations: Some observers believe the measures are drafted in retaliation to the Section 301 report of the US government which addresses Chinese investment in the United States as well as the US request of China for consultations of China over the Technology Import / Export Regulations, which are also referred to in these regulations. We are also unclear at this point if these regulations were previously “in the works” or otherwise accelerated in response to the Section 301 investigation.
Companies should consider consulting counsel on the impact of these regulations. First, it appears likely that a foreign-invested company’s acquisition of Chinese technology is an IP ‘transfer’ for purposes of these regulations. Under US law, these might be considered a “deemed export if a foreign national obtains technology while in the United States These regulations do not use this terminology. The regulations may impact foreign companies based on their source of capital rather than the presence of foreign nationals. For example, the regulation’s scope appears to include transfers that occur wholly within China, as they refer to transfers “to foreigners” of Chinese IP, and earlier regulations, by contrast, focused on transfers to enterprises overseas. .(本办法所述知识产权对外转让,是指中国单位或者个人将其境内知识产权转让给外国企业、个人或者其他组织.)Compare with the Provisional Regulations on the Administration of Technology Exports 技术出口管理·暂行办法 (对外经贸部/国家科委) (June 26, 1990) (本办法所称的技术出口是中国境内的 公司, 企业, 研究机构以及其·他组织或者个人(不包括外商投资企业, 外国在中国公司。。。。)向境外的公司。。。。). Further clarification on this important issue would be helpful.
Another issue requiring clarification is the difference between technology transfer from an assignment or licensing of a patent. This has been a subject of confusion under Chinese law for some time, and these regulations appear to carry that forward. The earlier 1990 regulations also regulated the transfer of patents, as well as registered trademarks (!) as a form of “technology transfer” (Art. 2). However, in most cases, any “leakage” of technology arising from a patent application occurred at the time of the publication of the patent application or grant. An added complication is that China already has procedures in place for regulating foreign filings of patents for national security purposes. Article 20.1 of the Chinese Patent Law provides for confidentiality examination of these applications. These measures be redundant with these procedures, particularly in regulating the transfer of patent applications to foreigners.
Until further clarity is established by implementing rules, these regulations could therefor have an impact of disrupting existing foreign invested R&D or cooperation across national borders. Two questions come immediately to mind: if, for example, a Chinese national is under contract to conduct R&D for a foreign invested company, or is an employee of that company, is the transfer in ownership of the patent application, from the employee to employer a “transfer of technology” for purposes of these regulations? Another question might be what is the standard applies to determine whether an invention created by individuals in China and overseas was created was created in China and its transfer is subject to these regulations? It is also worth noting that the 1990 regulations specifically exempted bilateral scientific cooperation (Article 2). These do not.
In a separate development, the State Council also released measures this week to strengthen security management of scientific data. The measures, which prioritize data security and focus on data sharing, order strengthening supervision of the use and sharing of scientific data, with both domestic and foreign parties.

Finally, this blog, and its preliminary observations, is not a substitute for legal counsel and serious research that is necessary on these and other issues arising under China’s export control regime. Please advise of any necessary corrections.

US Files Consultation Request at WTO on Chinese Technology Licensing Practices

Fresh on the heels of the Section 301 announcement, USTR on March 23, 2018 made a  consultation request  of China regarding China’s discriminatory licensing practices.  This is the first step in initiation of  a WTO dispute.  Here is a link to the press announcement.

The consultation request broadly speaking alleges discriminatory treatment in licensing pursuant to China’s joint venture regime as well as the  Administration of Technology Import/Export Regulations (“TIER”), as compared to provisions under China’s contract law that may govern purely domestic technology transfers or Chinese exports of technology.  The complaint is based on the National Treatment provisions of the TRIPS agreement as well as Article 28.2, which provides that “Patent owners shall also have the right to assign, or transfer by succession, the patent and to conclude licensing contracts.”  The Section 301 Report of USTR also discusses these issues.

 

 

 

October Offerings on Chinese IP

Here are some upcoming programs that involve China in North American in October:

October 11-12, 2017, I will be speaking on a China IP Panel at the ABA IP West conference in Long Beach, California.  The panel will focus on China’s recent (paradoxical) emergence in IP protection and enforcement.  Mike Mangelson, China IP Attaché in Shanghai will also be speaking at a session focused on the China IP Attaché program at this ABA program.

On October 14, 2017, I will be moderating a session on new trends in Chinese IP litigation, courts and enforcement at the Sixth Annual IP  Summit hosted by Loyola University of Los Angeles.

On October 18, 2017, the University of Indiana/USPTO will be hosting a China “Road Show” in Indianapolis.

On October 20, 2017, the John Marshall Law School will be hosting a China “Road Show” with USPTO in Chicago.

On October 26, 2018, I am scheduled to be commenting (as an academic) at the Fordham IP Institute on a presentation by Dr. David Cole of the Hagley Museum and Library on “A Nation of Inventors: The Politics of American Patent Models.  The Hagley Museum is planning an exhibit in China of its patent models in 2018.

Apart from these events, there are also China IP road shows scheduled for Salt Lake City and Denver in October.   Watch the USPTO website for more information on these and other programs.

An addenda to October offerings, per its Federal Register Notice, on October 10, 2017, USTR will be hosting a hearing on the Section 301 investigation involving China’s Technology Transfer, Intellectual Property and Innovation – Related Rractices.

 

GAI’s Comments on AUCL

Ahead of schedule, George Mason University’s Global Antitrust Institute (“GAI”) has prepared its comments on the NPC’s proposed revisions to the Anti-Unfair Competition Law, available here. 

GAI commended the National People’s Congress for deleting Article 6 on abuse of superior bargaining position and recommended that any provisions that relate to conduct covered by China’s Anti-Monopoly Law (AML) be omitted entirely. GAI also strongly urged that Article 11 (which provides that “[b]usiness operators selling goods must not bundle the sale of goods against buyers’ wishes, and must not attach other unreasonable conditions”) be omitted in its entirety, as such conduct is already covered by Article 17(5) of the AML or at the very least, Article 11 should be revised to adopt an effects-based approach.

In my opinion, the argument that the AUCL shouldn’t duplicate the AML can also be said of other laws in China, notably the Technology Import / Export Regulations and Article 329 of the Contract Law regarding monopolization of technology.  Other laws, such as the Pricing Law also have a strong overlap with the AML, particularly as administered by NDRC. 

GAI’s comments on a prior State Council Legislative Affairs Office draft, along with the comments of the American Bar Association and American Intellectual Property Law Institute are available through this link.

I hope to post the comments of other organizations on the AUCL on this blog in the future. If you would like your organization’s comments to be considered for distributing here, please send your comments to me at: chinaipr@yahoo.com.